Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Triazolam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 5/20 | 1.00 |
| ▸ | GABRA5 known ✓ | P31644 | 5/20 | 1.00 |
| ▸ | GABRA2 known ✓ | P47869 | 5/20 | 1.00 |
| ▸ | GABRA3 known ✓ | P34903 | 4/20 | 1.00 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 1.00 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 1.00 |
| ▸ | GABRB2 known ✓ | P47870 | 4/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 3/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.80 |
| ▸ | PTAFR | P25105 | 8/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | BRD4 | O60885 | 2/20 | 0.77 |
| ▸ | CNR1 | P21554 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triazolam SCHEMBL29382425 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL5142333 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL29368430 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL29349744 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL27600059 | 0.99 | GABRA1 (0.98) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL9055695 | 0.99 | GABRA1 (0.98) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL3262516 | 0.93 | GABRA1 (0.86) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| SCHEMBL13352295 | 0.91 | GABRA1 (0.83) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL28059256 | 0.89 | GABRA1 (0.79) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| SCHEMBL8274469 | 0.89 | GABRA1 (0.80) | GABRA1GABRA5GABRA2GABRA3OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 23174 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| WO-2026090360-A1 | FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260108529-A1 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| US-20260097039-A1 | METHODS FOR TREATING A FATTY LIVER DISEASE | MADRIGAL PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260076953-A1 | METHODS OF DIAGNOSING AND TREATING ADHD IN BIOMARKER POSITIVE SUBJECTS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-03-19 | — | — | US | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| US-12515030-B2 | Transdermal drug delivery devices and methods | MORNINGSIDE VENTURE INVESTMENTS LIMITED (MC) | 2026-01-06 | — | — | US | claimed |
| EP-0098113-B1 | A COMBINATION OF BETA-ADRENOCEPTOR ANTAGONISTS AND ANXIOLYTIC AGENTS | AYERST, MCKENNA AND HARRISON INC. (CA) | 1986-09-03 | — | — | EP | claimed |
| US-4588721-A | Treatment of negative symptoms of schizophrenia | THE UPJOHN COMPANY (US) | 1986-05-13 | — | — | US | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
| EP-0139460-A2 | Benzodiazepines and their therapeutic use | THE UPJOHN COMPANY (US) | 1985-05-02 | — | — | EP | claimed |
| EP-0098113-A1 | A combination of beta-adrenoceptor antagonists and anxiolytic agents | AYERST, MCKENNA AND HARRISON INC. (CA) | 1984-01-11 | — | — | EP | claimed |
| US-4316897-A | TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1982-02-23 | — | — | US | claimed |
| EP-0025546-A2 | Therapeutical use of tranquillizing benzodiazepine derivatives and mixtures containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-03-25 | — | — | EP | claimed |
| US-4000289-A | 6-PHENYL-4H-S-TRIAZOLO(4,3-A)(1,4)BENZODIAZEPINES | THE UPJOHN COMPANY (US) | 1976-12-28 | — | — | US | claimed |
| US-3987052-A | SEDATIVES, TRANQUILIZERS, MUSCLE RELAXANTS | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | claimed |
| US-3980790-A | 3980790 A)-(1,4)BENZODIAZEPINE COMPOSITIONS AND METHOD OF TREATMENTSOPORIF | THE UPJOHN COMPANY (US) | 1976-09-14 | — | — | US | claimed |